Corticorelin acetate
As of the edition of 20 October 2026, Corticorelin acetate is a protein: stopped in 2013; acts on CRHR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Protein
- Registered trials
- 5, 3 stopped early
- Disease areas
- Cancer; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Corticorelin acetate.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CRHR1 | Corticotropin-releasing hormone receptor 1 | P34998 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 0 | 0 | 2 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Celtic Pharma | Lead sponsor of trials | 2004 to now |
| PharmaNet | Lead sponsor of trials | 2008 to now |